Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04523272 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 15, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 2023 to Jun 2025 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 418 to confirmed 528 · Study sites: 26 to 39 · 1 morev3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 418 to confirmed 528
    • Study sites: 26 to 39
    • Completion date: Jun 2023 to Dec 2025
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2020 to Aug 25, 2020 · Site details revised at 26 of 26 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2020 to Aug 25, 2020
    • Site details revised at 26 of 26 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
Trial Details
NCT Number NCT04523272
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Renal Cancer
Enrollment 528 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov